Author | Cases n | Cotrolsa/Cohortb | Source population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
---|---|---|---|---|---|---|---|---|
Coogan et al. [26] | 491 | 5,833a | Hospital based | >4 days/week for >3 months. Continuing use during 1 year of lag time | Personal Interview | NSAIDs (7%) | 0.8 | 0.5–1.1 |
Langman et al. [36] | 513 | 1,535a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (7%) | 1.49 | 1.02–2.18 |
Menezes et al. [49] | 194 | 582a | Hospital based | >1 tablet/week for at least 6 months | In-hospital Questionnaire | Aspirin (44%) | 1.00 | 0.72–1.39 |
Schreinemachers et al. [43] | 30 | 12,668b | Cohort | Ever use of aspirin in the 30 days prior to start date | Mailed Questionnaire | Aspirin (59%) | 0.67 | 0.33–1.36 |
Anderson et al. [23] | 80 | 28,283b | Cohort | >6 times/week at baseline | Mailed Questionnaire | Aspirin (21%) | 0.40 | 0.20–0.82 |
 |  |  |  |  |  | NA-NSAIDs (NR) | 1.28 | 0.68–2.43 |